BACKGROUND: Smokers have a higher risk of developing non-small cell lung cancer (NSCLC) than never-smokers, but the relative risk of developing second primary lung cancer (SPLC) is unclear. Determining the risk of SPLC in smokers versus never-smokers after treatment of an initial cancer may help guide recommendations for long-term surveillance. METHODS: Patients who underwent resection for stage I adenocarcinoma were identified from a prospectively maintained institutional database. Patients with other histologies, synchronous lesions, or who received neoadjuvant or adjuvant therapy were excluded. The SPLCs were identified based on Martini criteria. RESULTS: From 1995 to 2012, a total of 2,151 patients underwent resection for stage I adenocarcinoma (308 never-smokers [14%] and 1,843 ever-smokers [86%]). SPLC developed in 30 never-smokers (9.9%) and 145 ever-smokers (7.8%). The SPLC was detected by surveillance computed tomography scan in the majority of patients (161; 92%). In total, 87% of never-smokers and 83% of ever-smokers had stage I SPLC. There was no significant difference in the cumulative incidence of SPLC between never-smokers and ever-smokers (p = 0.18) in a competing-risks analysis. The cumulative incidence at 10 years was 20.3% for never-smokers and 18.2% for ever-smokers. CONCLUSIONS: Although smokers have a greater risk of NSCLC, the risk of a second primary cancer developing after resection of stage I lung cancer is comparable between smokers and never-smokers. The majority of these second primary cancers are detectable at a curable stage. Ongoing postoperative surveillance should be recommended for all patients regardless of smoking status.
BACKGROUND: Smokers have a higher risk of developing non-small cell lung cancer (NSCLC) than never-smokers, but the relative risk of developing second primary lung cancer (SPLC) is unclear. Determining the risk of SPLC in smokers versus never-smokers after treatment of an initial cancer may help guide recommendations for long-term surveillance. METHODS:Patients who underwent resection for stage I adenocarcinoma were identified from a prospectively maintained institutional database. Patients with other histologies, synchronous lesions, or who received neoadjuvant or adjuvant therapy were excluded. The SPLCs were identified based on Martini criteria. RESULTS: From 1995 to 2012, a total of 2,151 patients underwent resection for stage I adenocarcinoma (308 never-smokers [14%] and 1,843 ever-smokers [86%]). SPLC developed in 30 never-smokers (9.9%) and 145 ever-smokers (7.8%). The SPLC was detected by surveillance computed tomography scan in the majority of patients (161; 92%). In total, 87% of never-smokers and 83% of ever-smokers had stage I SPLC. There was no significant difference in the cumulative incidence of SPLC between never-smokers and ever-smokers (p = 0.18) in a competing-risks analysis. The cumulative incidence at 10 years was 20.3% for never-smokers and 18.2% for ever-smokers. CONCLUSIONS: Although smokers have a greater risk of NSCLC, the risk of a second primary cancer developing after resection of stage I lung cancer is comparable between smokers and never-smokers. The majority of these second primary cancers are detectable at a curable stage. Ongoing postoperative surveillance should be recommended for all patients regardless of smoking status.
Authors: Michael J Thun; S Jane Henley; David Burns; Ahmedin Jemal; Thomas G Shanks; Eugenia E Calle Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: J Van Meerbeeck; J Weyler; A Thibaut; J Vansteenkiste; J Aumann; G Deneffe; D Galdermans; M Haelterman; G Joos; M Noppen; P Pinson; J Tasson; A van den Eeckhout; M Uydebrouck Journal: Lung Cancer Date: 1996-11 Impact factor: 5.705
Authors: E T Fontham; P Correa; P Reynolds; A Wu-Williams; P A Buffler; R S Greenberg; V W Chen; T Alterman; P Boyd; D F Austin Journal: JAMA Date: 1994-06-08 Impact factor: 56.272
Authors: Richard J Battafarano; Seth D Force; Bryan F Meyers; Jennifer Bell; Tracey J Guthrie; Joel D Cooper; G Alexander Patterson Journal: J Thorac Cardiovasc Surg Date: 2004-03 Impact factor: 5.209
Authors: David Rice; Hyung-Woo Kim; Anita Sabichi; Scott Lippman; J Jack Lee; Brendell Williams; Ara Vaporciyan; W Roy Smythe; Stephen Swisher; Garrett Walsh; Joe B Putnam; Waun Ki Hong; Jack Roth Journal: Ann Thorac Surg Date: 2003-10 Impact factor: 4.330
Authors: Yusuke Takahashi; Takashi Eguchi; Shaohua Lu; Robert J Downey; David R Jones; William D Travis; Prasad S Adusumilli Journal: Am J Respir Crit Care Med Date: 2018-03-15 Impact factor: 21.405
Authors: Summer S Han; Gabriel A Rivera; Martin C Tammemägi; Sylvia K Plevritis; Scarlett L Gomez; Iona Cheng; Heather A Wakelee Journal: J Clin Oncol Date: 2017-06-23 Impact factor: 44.544
Authors: Hari B Keshava; Kay See Tan; Joe Dycoco; James Huang; Alison Berkowitz; Dyana Sumner; Amy Devigne; Prasad Adusumilli; Manjit Bains; Matthew Bott; James Isbell; Robert Downey; Daniela Molena; Bernard Park; Gaetano Rocco; Smita Sihag; David R Jones; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2021-11-20 Impact factor: 6.439
Authors: C Matthew Kinsey; Katharine L Hamlington; Jacqueline O'Toole; Renee Stapleton; Jason H T Bates Journal: PLoS One Date: 2016-11-02 Impact factor: 3.240
Authors: Jacqueline V Aredo; Sophia J Luo; Rebecca M Gardner; Nilotpal Sanyal; Eunji Choi; Thomas P Hickey; Thomas L Riley; Wen-Yi Huang; Allison W Kurian; Ann N Leung; Lynne R Wilkens; Hilary A Robbins; Elio Riboli; Rudolf Kaaks; Anne Tjønneland; Roel C H Vermeulen; Salvatore Panico; Loïc Le Marchand; Christopher I Amos; Rayjean J Hung; Neal D Freedman; Mattias Johansson; Iona Cheng; Heather A Wakelee; Summer S Han Journal: J Thorac Oncol Date: 2021-03-17 Impact factor: 20.121